Allogene Therapeutics
Farah Fawaz is a highly experienced professional in the biopharmaceutical industry, currently serving as Senior Vice President at Allogene Therapeutics since October 2018, with a focus on GxP Quality and Compliance and CMC Quality. Prior to this role, Fawaz held the position of Executive Director of Commercial QC at Intarcia Therapeutics, Inc., and spent nearly a decade at Bayer HealthCare in various roles, including Director of Quality Control and Analytical Chemistry. Fawaz began the career as a Senior Scientist at Berlex and previously worked as a Post-doctoral fellow at the University of California, San Francisco. Fawaz holds a Ph.D. in Cellular and Molecular Biology from the University of Michigan and a B.S. in Biology from the American University of Beirut.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.